Juvenile myelomonocytic leukemia; moving forward

Affiliations

¹ Department of Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA. txelghet@texaschildrens.org.
² Université Paris Cité, Institut de recherche Saint-Louis and the Department of Genetics, Robert Debré Hospital, Paris, France.
³ Pathology Unit, Department of Laboratories, Bambino Gesù Children's Hospital, Rome, Italy.
⁴ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
⁵ Department of Hematology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.
⁶ Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.

Comment

M Tarek Elghetany et al. Leukemia. 2023 Mar.

. 2023 Mar;37(3):720-722.

doi: 10.1038/s41375-023-01818-y. Epub 2023 Jan 20.

¹ Department of Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA. txelghet@texaschildrens.org.
² Université Paris Cité, Institut de recherche Saint-Louis and the Department of Genetics, Robert Debré Hospital, Paris, France.
³ Pathology Unit, Department of Laboratories, Bambino Gesù Children's Hospital, Rome, Italy.
⁴ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
⁵ Department of Hematology, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.
⁶ Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.

No abstract available

Comment on

Classification of rare pediatric myeloid neoplasia-Quo vadis?
Niemeyer CM, Rudelius M, Shimamura A, Flotho C, Hasle H, Stieglitz E, Strahm B, Godley LA, Weinberg OK, Orazi A, Calvo KR. Niemeyer CM, et al. Leukemia. 2022 Dec;36(12):2947-2948. doi: 10.1038/s41375-022-01731-w. Epub 2022 Oct 21. Leukemia. 2022. PMID: 36271151 No abstract available.

1. Niemeyer CM, Rudelius M, Shimamura A, Flotho C, Hasle H, Stieglitz E, et al. Classification of rare pediatric myeloid neoplasia-Quo vadis? Leukemia. 2022;36:2947–8. - DOI - PubMed
1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. - DOI - PubMed - PMC
1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. - DOI - PubMed
1. Alaggio R, Carneiro F, Chan JKC, Cheung ANY, Cree IA, Denton E, et al. (Eds), WHO Classification of Tumours: Paediatric tumours [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022 [cited 2022/11/22]. (WHO Classification of Tumours series, 5th ed.; vol. 7). Available from: https://tumourclassification.iarc.who.int/chapters/44 .
1. Strullu M, Caye A, Cassinat B, Fenneteau O, Touzot F, Blauwblomme T, et al. In hematopoietic cells with a germline mutation of CBL, loss of heterozygosity is not a signature of juvenile myelo-monocytic leukemia. Leukemia. 2013;27:2404–7. - DOI - PubMed